EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Dose reduced induction therapy (A)-AIDA in patients with AML, being unfit for standard 7+3 chemotherapy and Literature Review of AML treatment in unfit/older AML patients

Karin Mayer, Leonie Birk, Katjana Schwab, Ingo G H Schmidt-Wolf, Marie von Lilienfeld-Toal, Peter Brossart, Axel Glasmacher, Corinna Hahn-Ast

Acta Haematologica · 2025

DOI: 10.1159/000545792 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Haematologica, 2025. Verfasst von Karin Mayer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medizinische Klinik III, Hämatologie/Onkologie/Rheumatologie, Universitätsklinikum Bonn, Bonn, Germany, karin.mayer@ukbonn.de. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Induction Chemotherapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) is 7 days cytarabine and 3 days daunorubicin. However older and frail patients cannot be treated intensively. Before hypomethylating agents (HMA) plus venetoclax (VEN) was established we formulated a more tolerable induction therapy for these patients using continuous infusions of reduced doses of cytarabine (A) and idarubicin (IDA) in combination with ATRA (A), the (A)-AIDA regimen and trying to reach noteworthy and relevant remission rates with acceptable toxicities in this special population.

Methods

Between 1998 and 2015 older/frail patients with newly diagnosed or relapsed AML received (A)-AIDA. Treatment consisted of cytarabine 100mg/m2/d d1-5 and idarubicin 5mg/m2/d d1-5 as continuous infusion. Since 2003 ATRA (45 mg/m²/d d4-6, 15 mg/m²/d d7-28) was added in some patients.

Results

154 patients received (A)-AIDA, median age was 71 years. In 40% the AML was secondary, 15.6% had relapsed AML. The complete remission rate was 41%, 7% reached a partial remission, the median overall survival was7 months. No significant differences of remission rates regarding various known risk factors for outcome with (A)-AIDA were detected. Conlusion: Recent studies established HMA/venetoclax as first-line treatment for older/frail AML patients. Because (A)-AIDA is equally effective in patients with secondary or relapsed AML or ECOG>1, this regimen is an interesting treatment option for patients uneligible to HMA/venetoclax regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsInduction ChemotherapyHumansAgedMaleFemaleCytarabineAged, 80 and overIdarubicinMiddle AgedRemission Induction

Stichwörter der Autor:innen

Acute myeloid leukemiaComplete remissionFrail patientsHypomethylating agentsInduction chemotherapyUnfitVenetoclax

Substanzen

CytarabineIdarubicin

Autor:innen und Institutionen

  • Medizinische Klinik III, Hämatologie/Onkologie/Rheumatologie, Universitätsklinikum Bonn, Bonn, Germany, karin.mayer@ukbonn.de.
  • Medizinische Klinik III, Hämatologie/Onkologie/Rheumatologie, Universitätsklinikum Bonn, Bonn, Germany.
  • Abteilung für Integrierte Onkologie, CIO Bonn, Universitätsklinikum Bonn, Bonn, Germany.
  • Institut für Diversitätsmedizin, Ruhr-Universität Bochum, Bochum, Germany.

Zitieren

APA

Mayer, K., Birk, L., Schwab, K., Schmidt-Wolf, I. G. H., von Lilienfeld-Toal, M., Brossart, P., Glasmacher, A., & Hahn-Ast, C. (2025). Dose reduced induction therapy (A)-AIDA in patients with AML, being unfit for standard 7+3 chemotherapy and Literature Review of AML treatment in unfit/older AML patients. Acta Haematologica. https://doi.org/10.1159/000545792

Vancouver

Mayer K, Birk L, Schwab K, Schmidt-Wolf IGH, von Lilienfeld-Toal M, Brossart P, et al. Dose reduced induction therapy (A)-AIDA in patients with AML, being unfit for standard 7+3 chemotherapy and Literature Review of AML treatment in unfit/older AML patients. Acta Haematologica. 2025. doi:10.1159/000545792

BibTeX
@article{Mayer2025,
  author = {Mayer, Karin and Birk, Leonie and Schwab, Katjana and Schmidt-Wolf, Ingo G H and von Lilienfeld-Toal, Marie and Brossart, Peter and Glasmacher, Axel and Hahn-Ast, Corinna},
  title = {Dose reduced induction therapy (A)-AIDA in patients with AML, being unfit for standard 7+3 chemotherapy and Literature Review of AML treatment in unfit/older AML patients},
  journal = {Acta Haematologica},
  year = {2025},
  doi = {10.1159/000545792}
}
Kostenlos starten →